These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 25238116)

  • 1. A European perspective on orally inhaled products: in vitro requirements for a biowaiver.
    García-Arieta A
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):419-29. PubMed ID: 25238116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. International Guidelines for Bioequivalence of Locally Acting Orally Inhaled Drug Products: Similarities and Differences.
    Lu D; Lee SL; Lionberger RA; Choi S; Adams W; Caramenico HN; Chowdhury BA; Conner DP; Katial R; Limb S; Peters JR; Yu L; Seymour S; Li BV
    AAPS J; 2015 May; 17(3):546-57. PubMed ID: 25758352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory Considerations for Approval of Generic Inhalation Drug Products in the US, EU, Brazil, China, and India.
    Lee SL; Saluja B; García-Arieta A; Santos GM; Li Y; Lu S; Hou S; Rebello J; Vaidya A; Gogtay J; Purandare S; Lyapustina S
    AAPS J; 2015 Sep; 17(5):1285-304. PubMed ID: 26002510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.
    García-Arieta A; Morales-Alcelay S; Herranz M; de la Torre-Alvarado JM; Blázquez-Pérez A; Suárez-Gea ML; Alvarez C
    Int J Pharm; 2012 Feb; 423(2):321-5. PubMed ID: 22120644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols. Part 3. Final report on a statistical procedure for determining equivalence.
    Christopher D; Adams W; Amann A; Bertha C; Byron PR; Doub W; Dunbar C; Hauck W; Lyapustina S; Mitchell J; Morgan B; Nichols S; Pan Z; Singh GJ; Tougas T; Tsong Y; Wolff R; Wyka B
    AAPS PharmSciTech; 2007 Nov; 8(4):E90. PubMed ID: 18181550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Discriminatory Power of the BCS-Based Biowaiver: A Retrospective With Focus on Essential Medicines.
    Hofsäss MA; Dressman JB
    J Pharm Sci; 2019 Sep; 108(9):2824-2837. PubMed ID: 31059698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demonstrating Bioequivalence of Locally Acting Orally Inhaled Drug Products (OIPs): Workshop Summary Report.
    Adams WP; Ahrens RC; Chen ML; Christopher D; Chowdhury BA; Conner DP; Dalby R; Fitzgerald K; Hendeles L; Hickey AJ; Hochhaus G; Laube BL; Lucas P; Lee SL; Lyapustina S; Li B; O'Connor D; Parikh N; Parkins DA; Peri P; Pitcairn GR; Riebe M; Roy P; Shah T; Singh GJ; Sharp SS; Suman JD; Weda M; Woodcock J; Yu L
    J Aerosol Med Pulm Drug Deliv; 2010 Feb; 23(1):1-29. PubMed ID: 20131983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of comparative performance of orally inhaled drug products in view of the classical bioequivalence paradigms: an analysis of the current scientific and regulatory dilemmas of inhaler evaluation.
    Horhota ST
    J Aerosol Med Pulm Drug Deliv; 2014 Dec; 27(6):408-13. PubMed ID: 25237840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Silico Methods for Development of Generic Drug-Device Combination Orally Inhaled Drug Products.
    Walenga RL; Babiskin AH; Zhao L
    CPT Pharmacometrics Syst Pharmacol; 2019 Jun; 8(6):359-370. PubMed ID: 31044532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Equivalence considerations for orally inhaled products for local action-ISAM/IPAC-RS European Workshop report.
    Evans C; Cipolla D; Chesworth T; Agurell E; Ahrens R; Conner D; Dissanayake S; Dolovich M; Doub W; Fuglsang A; García Arieta A; Golden M; Hermann R; Hochhaus G; Holmes S; Lafferty P; Lyapustina S; Nair P; O'Connor D; Parkins D; Peterson I; Reisner C; Sandell D; Singh GJ; Weda M; Watson P
    J Aerosol Med Pulm Drug Deliv; 2012 Jun; 25(3):117-39. PubMed ID: 22413806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Vitro Testing for Orally Inhaled Products: Developments in Science-Based Regulatory Approaches.
    Forbes B; Bäckman P; Christopher D; Dolovich M; Li BV; Morgan B
    AAPS J; 2015 Jul; 17(4):837-52. PubMed ID: 25940082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing bioequivalence for inhaled drugs; weighing the evidence.
    Daley-Yates PT; Parkins DA
    Expert Opin Drug Deliv; 2011 Oct; 8(10):1297-308. PubMed ID: 21699442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory Considerations of Bioequivalence Studies for Oral Solid Dosage Forms in Japan.
    Kuribayashi R; Takishita T; Mikami K
    J Pharm Sci; 2016 Aug; 105(8):2270-7. PubMed ID: 27372551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Demonstrating comparative in vitro bioequivalence for animal drug products through chemistry and manufacturing controls and physicochemical characterization: a proposal.
    Martinez MN; Fahmy R
    AAPS J; 2015 Mar; 17(2):307-12. PubMed ID: 25609223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds.
    Mayers I; Bhutani M
    J Aerosol Med Pulm Drug Deliv; 2018 Feb; 31(1):18-24. PubMed ID: 28708443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations in establishing bioequivalence of inhaled compounds.
    Mayers I; Bhutani M
    Expert Opin Drug Deliv; 2018 Feb; 15(2):153-162. PubMed ID: 28918665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of the modified chi-square ratio statistic in a stepwise procedure for cascade impactor equivalence testing.
    Weber B; Lee SL; Delvadia R; Lionberger R; Li BV; Tsong Y; Hochhaus G
    AAPS J; 2015 Mar; 17(2):370-9. PubMed ID: 25515206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The US and EU regulatory landscapes for locally acting generic/hybrid inhalation products intended for treatment of asthma and COPD.
    Fuglsang A
    J Aerosol Med Pulm Drug Deliv; 2012 Aug; 25(4):243-7. PubMed ID: 22857274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generics and cost-effective prescribing in Belgium: does bioequivalence always translate in therapeutic equivalence?
    Dupont AG; Heller F
    Acta Clin Belg; 2009; 64(5):406-14. PubMed ID: 19999388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.